Improved assay for fecal calprotectin

被引:171
作者
Ton, H [1 ]
Brandsnes, O
Dale, S
Holtlund, J
Skuibina, E
Schjonsby, H
Johne, B
机构
[1] Nycomed Pharma AS, Oslo, Norway
[2] Parexel Medstat Res, Lillestrom, Norway
[3] Aker Univ Hosp, Oslo, Norway
关键词
calprotectin; feces; ELISA;
D O I
10.1016/S0009-8981(99)00206-5
中图分类号
R446 [实验室诊断]; R-33 [实验医学、医学实验];
学科分类号
1001 ;
摘要
Fecal calprotectin is a marker of inflammatory and neoplastic disease in the lower gastrointestinal tract. A new fecal sample preparation procedure for the measurement of calprotectin has been developed, with higher calprotectin yield and lower contamination risk. Changes in the new method compared to the original [Roseth AG, Fagerhol MK, Aadland E, Schonsby H. Assessment of the neutrophil dominating protein calprotectin in feces. A methodologic study. Scand J Gastroenterol 1992;27(9):793-798] are smaller sample size, higher dilution of the sample, presence of dissociating agents in the extraction solution and procedure performed in closed disposable tubes. The extraction yield was 78% (41-100%) of total calprotectin, giving an overall five-fold increase compared to the original method. Samples with high calprotectin values were increased to a slightly higher degree, than low calprotectin samples, thus improving the separation between high and low calprotectin levels. Median calprotectin level in healthy subjects was 26 mu g/g. Pathological samples with pancolitis showed levels up to 30 000 mu g/g. The mean C.V. (coefficient of variation) in blended feces was lower than that of unblended, suggesting uneven distribution of calprotectin. However, no significant difference between spot measurements was found when five samples from each of 47 stools were measured. Thus measurements of calprotectin in fecal samples were accurate and reproducible. No interference with foods or relevant oral pharmaceuticals or nutraceuticals was found. (C) 2000 Elsevier Science B.V. All rights reserved.
引用
收藏
页码:41 / 54
页数:14
相关论文
共 37 条
[11]  
DELABIE J, 1990, CLIN EXP IMMUNOL, V81, P123
[12]   CALPROTECTIN IN CEREBROSPINAL-FLUID OF THE HIV INFECTED - A DIAGNOSTIC MARKER OF OPPORTUNISTIC CENTRAL-NERVOUS-SYSTEM INFECTION [J].
DUNLOP, O ;
BRUUN, JN ;
MYRVANG, B ;
FAGERHOL, MK .
SCANDINAVIAN JOURNAL OF INFECTIOUS DISEASES, 1991, 23 (06) :687-689
[13]  
Fagerhol M. K., 1990, STIMULUS RESPONSE CO, P187
[14]  
FAGERHOL MK, 1980, SCAND J HAEMATOL, V24, P393
[15]   Fecal marker variability in colorectal cancer: Calprotectin versus hemoglobin [J].
Gilbert, JA ;
Ahlquist, DA ;
Mahoney, DW ;
Zinsmeister, AR ;
Rubin, J ;
Ellefson, RD .
SCANDINAVIAN JOURNAL OF GASTROENTEROLOGY, 1996, 31 (10) :1001-1005
[16]   MEASUREMENT OF FECAL LACTOFERRIN AS A MARKER OF FECAL LEUKOCYTES [J].
GUERRANT, RL ;
ARAUJO, V ;
SOARES, E ;
KOTLOFF, K ;
LIMA, AAM ;
COOPER, WH ;
LEE, AG .
JOURNAL OF CLINICAL MICROBIOLOGY, 1992, 30 (05) :1238-1242
[17]  
Guerrant RL, 1996, J CLIN MICROBIOL, V34, P2337
[18]  
Johne B, 1997, J CLIN PATHOL-MOL PA, V50, P113
[19]   Fecal calprotectin concentration in patients with colorectal carcinoma [J].
Kristinsson, J ;
Roseth, A ;
Fagerhol, MK ;
Aadland, E ;
Schjonsby, H ;
Bormer, OP ;
Raknerud, N ;
Nygaard, K .
DISEASES OF THE COLON & RECTUM, 1998, 41 (03) :316-321
[20]  
KRISTINSSON J, 1998, WORLD C GASTR VIENN